NZ513742A - Combinations of formoterol and mometasone furoate for asthma - Google Patents

Combinations of formoterol and mometasone furoate for asthma

Info

Publication number
NZ513742A
NZ513742A NZ513742A NZ51374200A NZ513742A NZ 513742 A NZ513742 A NZ 513742A NZ 513742 A NZ513742 A NZ 513742A NZ 51374200 A NZ51374200 A NZ 51374200A NZ 513742 A NZ513742 A NZ 513742A
Authority
NZ
New Zealand
Prior art keywords
medicament according
medicament
formoterol
dry powder
dispersion
Prior art date
Application number
NZ513742A
Other languages
English (en)
Inventor
Ian Francis Hassan
Jeremy Guy Clarke
Henry Luke Danahay
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10848904&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ513742(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NZ513742A publication Critical patent/NZ513742A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NZ513742A 1999-03-03 2000-03-01 Combinations of formoterol and mometasone furoate for asthma NZ513742A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9904919.9A GB9904919D0 (en) 1999-03-03 1999-03-03 Organic compounds

Publications (1)

Publication Number Publication Date
NZ513742A true NZ513742A (en) 2001-09-28

Family

ID=10848904

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ513742A NZ513742A (en) 1999-03-03 2000-03-01 Combinations of formoterol and mometasone furoate for asthma

Country Status (27)

Country Link
US (4) US20020055494A1 (enExample)
EP (2) EP1325765A1 (enExample)
JP (3) JP2002538110A (enExample)
KR (1) KR100682418B1 (enExample)
CN (1) CN1196478C (enExample)
AT (1) ATE241970T1 (enExample)
AU (1) AU770739B2 (enExample)
BR (1) BR0008699A (enExample)
CA (1) CA2362499C (enExample)
CL (1) CL2004001170A1 (enExample)
CZ (1) CZ294089B6 (enExample)
DE (1) DE60003160T2 (enExample)
DK (1) DK1156790T3 (enExample)
ES (1) ES2200837T3 (enExample)
GB (1) GB9904919D0 (enExample)
HK (1) HK1043048B (enExample)
HU (1) HU229073B1 (enExample)
ID (1) ID30171A (enExample)
IL (1) IL144351A (enExample)
NO (1) NO331428B1 (enExample)
NZ (1) NZ513742A (enExample)
PL (1) PL212355B1 (enExample)
PT (1) PT1156790E (enExample)
RU (1) RU2270670C2 (enExample)
SK (1) SK286338B6 (enExample)
WO (1) WO2000051591A1 (enExample)
ZA (1) ZA200106442B (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9616237D0 (en) 1996-08-01 1996-09-11 Norton Healthcare Ltd Aerosol formulations
GB9904919D0 (en) * 1999-03-03 1999-04-28 Novartis Ag Organic compounds
GB9928311D0 (en) * 1999-11-30 2000-01-26 Novartis Ag Organic compounds
GB0009612D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Therapeutic formulations
GB0012260D0 (en) 2000-05-19 2000-07-12 Astrazeneca Ab Novel composition
US20020076382A1 (en) * 2000-08-04 2002-06-20 Kaplan Leonard W. Formulations of mometasone and a bronchodilator for pulmonary administration
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
TWI324934B (en) * 2001-08-28 2010-05-21 Schering Corp Pharmaceutical compositions for the treatment of asthma
LT3494995T (lt) * 2002-03-01 2020-04-10 Chiesi Farmaceutici S.P.A. Ypatingai smulki formoterolio kompozicija
GB0207906D0 (en) 2002-04-05 2002-05-15 3M Innovative Properties Co Formoterol and mometasone aerosol formulations
EP1878664B1 (en) * 2002-08-27 2011-03-30 Schering Corporation Process for producing metered dose inhaler formulations
US20040043064A1 (en) * 2002-08-29 2004-03-04 Iorio Theodore L. Dosage forms having reduced moisture transmission
SE527200C2 (sv) * 2003-06-19 2006-01-17 Microdrug Ag Inhalatoranordning samt kombinerade doser av formaterol och fluticason
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
CA2540005A1 (en) * 2003-09-26 2005-04-07 Schering Corporation Pulmonary disease treatment
GB0323684D0 (en) 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
AU2004285447A1 (en) * 2003-10-20 2005-05-12 Schering Corporation Pharmaceutical compositions
WO2005037245A2 (en) * 2003-10-21 2005-04-28 Direct-Haler A/S A multiple route medication for the treatment of rhinitis and asthma
WO2006105401A2 (en) * 2005-03-30 2006-10-05 Schering Corporation Medicaments and methods combining an anticholinergic, a corticosteroid, and a long acting beta agonist
US20070099883A1 (en) * 2005-10-07 2007-05-03 Cheryl Lynn Calis Anhydrous mometasone furoate formulation
WO2007059620A1 (en) * 2005-11-23 2007-05-31 Feanny Stephen J Method for administering formoterol using a nebulizer
US20080253970A1 (en) * 2007-02-09 2008-10-16 Schering Corporation Stable Pharmaceutical Drug Products
US20080294720A1 (en) * 2007-05-21 2008-11-27 International Business Machines Corporation Enhanced Online Collaboration System
US8898316B2 (en) * 2007-05-30 2014-11-25 International Business Machines Corporation Enhanced online collaboration system for viewers of video presentations
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
PT3111927T (pt) * 2009-05-29 2020-03-03 Pearl Therapeutics Inc Composições para administração respiratória de agentes ativos e métodos e sistemas associados
GB0918149D0 (en) 2009-10-16 2009-12-02 Jagotec Ag Improved medicinal aerosol formulation
WO2011093815A2 (en) * 2010-01-29 2011-08-04 Mahmut Bilgic Pharmaceutical compositions comprising formoterol and mometasone
US20130177651A1 (en) * 2010-09-03 2013-07-11 Pharmaterials Limited Pharmaceutical Composition Suitable for Use in a Dry Powder Inhaler
CN102416179B (zh) 2010-09-28 2014-05-07 益得生物科技股份有限公司 用于哮喘的吸入性复方组合物
GB201113662D0 (en) * 2011-08-08 2011-09-21 Prosonix Ltd Pharmaceutical compositions
US10111957B2 (en) * 2012-07-05 2018-10-30 Arven Ilac Snayi ve Ticaret A.S. Inhalation compositions comprising glucose anhydrous
WO2014007771A2 (en) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalation compositions comprising muscarinic receptor antagonist
TR201902687T4 (tr) 2013-03-15 2019-03-21 Pearl Therapeutics Inc İri parçacıklı kristal malzemelerin koşullandırılması için yöntemler ve sistemler.
ITMI20130571A1 (it) * 2013-04-10 2014-10-11 Zambon Spa Composizione farmaceutica contenente budesonide e formoterolo
US9427376B2 (en) * 2013-10-10 2016-08-30 Chiesi Farmaceutici S.P.A. Process for preparing pharmaceutical formulations for inhalation comprising a high-dosage strength active ingredient
MX372705B (es) * 2014-10-08 2020-06-18 Zambon Spa Composición farmacéutica que contiene budesonida y formoterol
CN108289843B (zh) 2015-12-04 2021-08-17 墨西哥氟石股份公司 药物组合物
GB2545025A (en) * 2015-12-04 2017-06-07 Mexichem Fluor Sa De Cv Pharmaceutical composition
CN115813935A (zh) * 2021-09-16 2023-03-21 上海上药信谊药厂有限公司 药物组合物、气雾剂及其制备方法和气雾剂产生系统
CN116763797B (zh) * 2022-03-09 2025-09-02 上海医药工业研究院有限公司 一种药物组合微球、其制备方法及其原料组合物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL95590A (en) 1989-09-08 1996-06-18 Glaxo Group Ltd Medicinal preparations containing Salmetrol and Pluticasone Propionate
SE9302777D0 (sv) * 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
US5874063A (en) 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
WO1993011773A1 (en) 1991-12-18 1993-06-24 Aktiebolaget Astra New combination of formoterol and budesonide
US6596260B1 (en) 1993-08-27 2003-07-22 Novartis Corporation Aerosol container and a method for storage and administration of a predetermined amount of a pharmaceutically active aerosol
US5837699A (en) 1994-01-27 1998-11-17 Schering Corporation Use of mometasone furoate for treating upper airway passage diseases
PE44995A1 (es) 1994-01-27 1995-12-18 Schering Corp Furoato de mometasona para el tratamiento de las enfermedades pulmonares y de las vias respiratorias
SK81197A3 (en) 1994-12-22 1997-11-05 Astra Ab Aerosol drug formulations, method for production thereof and its use
SE9700135D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
AU718967B2 (en) * 1997-02-05 2000-05-04 Jagotec Ag Medical aerosol formulations
CZ295460B6 (cs) * 1997-03-20 2005-08-17 Schering Corporation Způsob výroby aglomerátů a jednotková dávka farmakologicky aktivní látky je obsahující
DE69804998T2 (de) * 1997-10-09 2002-12-12 Schering Corp., Kenilworth Mometasonfuroat-suspensionen zum zerstäuben
MY133181A (en) * 1998-09-10 2007-10-31 Schering Corp Methods and compositions for treating sinusitis, otitis media and other related disorders using antihistamines
GB9904919D0 (en) * 1999-03-03 1999-04-28 Novartis Ag Organic compounds
TWI324934B (en) * 2001-08-28 2010-05-21 Schering Corp Pharmaceutical compositions for the treatment of asthma

Also Published As

Publication number Publication date
KR100682418B1 (ko) 2007-02-15
ATE241970T1 (de) 2003-06-15
PL212355B1 (pl) 2012-09-28
HK1043048B (en) 2004-01-30
EP1325765A1 (en) 2003-07-09
EP1156790A1 (en) 2001-11-28
CA2362499A1 (en) 2000-09-08
US20020055494A1 (en) 2002-05-09
IL144351A (en) 2005-12-18
JP5663046B2 (ja) 2015-02-04
SK12302001A3 (sk) 2001-12-03
NO20013988L (no) 2001-08-16
US20030050290A1 (en) 2003-03-13
JP2013067668A (ja) 2013-04-18
DK1156790T3 (da) 2003-09-29
AU770739B2 (en) 2004-03-04
PT1156790E (pt) 2003-10-31
CN1196478C (zh) 2005-04-13
NO20013988D0 (no) 2001-08-16
HU229073B1 (en) 2013-07-29
IL144351A0 (en) 2002-05-23
JP5646828B2 (ja) 2014-12-24
ID30171A (id) 2001-11-08
US7566705B2 (en) 2009-07-28
WO2000051591A1 (en) 2000-09-08
DE60003160D1 (de) 2003-07-10
JP2010001295A (ja) 2010-01-07
DE60003160T2 (de) 2004-05-19
KR20010102473A (ko) 2001-11-15
US20040105822A1 (en) 2004-06-03
CN1341017A (zh) 2002-03-20
BR0008699A (pt) 2001-12-26
ZA200106442B (en) 2002-09-05
HK1043048A1 (en) 2002-09-06
EP1156790B1 (en) 2003-06-04
US7067502B2 (en) 2006-06-27
JP2002538110A (ja) 2002-11-12
RU2270670C2 (ru) 2006-02-27
CL2004001170A1 (es) 2005-03-28
ES2200837T3 (es) 2004-03-16
CZ294089B6 (cs) 2004-10-13
HUP0200142A2 (en) 2002-06-29
GB9904919D0 (en) 1999-04-28
CA2362499C (en) 2009-01-27
NO331428B1 (no) 2011-12-27
AU3284300A (en) 2000-09-21
CZ20013168A3 (cs) 2001-12-12
SK286338B6 (en) 2008-07-07
US20060009437A1 (en) 2006-01-12

Similar Documents

Publication Publication Date Title
CA2362499C (en) Combinations of formoterol and mometasone furoate for asthma
AU758999B2 (en) Combinations of formoterol and fluticasone propionate for asthma
CA2360248C (en) Combinations of formoterol and a tiotropium salt
HK1042429B (en) Combinations of formoterol and fluticasone propionate for asthma
MXPA01008879A (en) Combinations of formoterol and mometasone furoate for asthma
MXPA01008360A (en) Combinations of formoterol and fluticasone propionate for asthma
MXPA01008001A (en) Combinations of formoterol and a tiotropium salt

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 7 YEARS UNTIL 01 MAR 2020 BY CPA GLOBAL

Effective date: 20130204

EXPY Patent expired